Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 23Completed 11Active not recruiting 11Not yet recruiting 4Unknown 3Terminated 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Radiation Injuries 1Prostatic Neoplasms 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Frailty 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 116Bevacizumab 102Capecitabine 100Oxaliplatin 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 85pembrolizumab 77Specimen Handling 77toripalimab 70Magnetic Resonance Spectroscopy 63Injections 63Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 51fludarabine 47Standard of Care 45Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43venetoclax 42Leucovorin 42lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Photons × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

OHSU Knight Cancer Institute

Phase 2 Not yet recruiting
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05548504 2022-09-21

HERAN2

Odense University Hospital

Phase 2 Not yet recruiting
182 enrolled
Thoracic

Frailty, Carcinoma, Non-Small-Cell Lung, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡